Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
REDWOOD CITY, Calif, Nov. 02, 2017 -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will report third quarter 2017 financial results after market close on Thursday, November 9, 2017. Codexis management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss financial results and provide a company update.
| Live Call: | U.S. | 855 890 8665 | ||||
| International | 720 634 2938 | |||||
| Passcode | 5797258 | |||||
| Live Webcast: | Codexis IR Website | |||||
| The webcast will be archived for 30 days. | ||||||
| Replay: | U.S. | 855 859 2056 | ||||
| International | 404 537 3406 | |||||
| Passcode | 5797258 | |||||
| The replay will be available for 48 hours | ||||||
About Codexis, Inc.
Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for commercial manufacture of pharmaceuticals and fine chemicals, as well as the development of enzymes as biotherapeutics and for molecular diagnostics. Codexis’ proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. For more information, see www.codexis.com.
CONTACTS
Investors
LHA Investor Relations
Jody Cain, 310 691 7100
[email protected]
